

Trends in community-acquired pneumonia hospitalisations and associated cardiovascular risk in Portugal, 2010–2018

Joana Carneiro¹, Rita Teixeira², Andreia Leite^{3,4}, Maria Lahuerta⁵, Julie Catusse⁵, Mohammad Ali⁵, Sílvia Lopes³

Affiliations: 1. NOVA National School of Public Health, NOVA University Lisbon, Lisbon, Portugal. 2. Vaccines, Pfizer Inc, Lisbon, Portugal. 3. NOVA National School of Public Health, Public Health Research Centre, Comprehensive Health Research Center, CHRC, REAL, CCAL, NOVA University Lisbon, Lisbon, Portugal. 4. Department of Epidemiology, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal. 5. Global Respiratory Vaccines, Pfizer Inc, Pennsylvania, USA.

Conflicts of interest: Joana Carneiro is a researcher at NOVA National School of Public Health working on a project funded by Pfizer, Inc. Rita Teixeira, Maria Lahuerta, Julie Catusse, and Mohammad Ali are employees of Pfizer, Inc. and may hold stocks or stock options. Andreia Leite coordinated a project funded by Pfizer, Inc. and is employee of NOVA National School of Public Health. Sílvia Lopes coordinates a project funded by Pfizer, Inc. and is employee of NOVA National School of Public Health.

Background

- Community-acquired pneumonia (CAP) is a major cause of hospitalisation, with substantial morbidity, mortality, and costs.(1)
- Cardiovascular diseases are a leading cause of mortality worldwide and over 80% of deaths related to those diseases are attributed to heart attack and stroke.(2)
- Studies outside Portugal have shown a link between CAP and cardiovascular disease.(3-5)

Aims

We aimed to better understand CAP hospitalisations in Portugal, in terms of their trends and risk of subsequent acute cardiovascular events.

CAP-H trends

CVD after CAP-H

Methods | CAP-H trends

Study design • Retrospective cohort study

Population • Adults (≥18y) living in mainland Portugal.
• Discharged with CAP from a public hospital between 2010-18 (ICD-9/10-CM codes used).

Variables • Frequency and incidence of CAP hospitalisation
• Subgroups: gender, age group, comorbidity, and year of discharge.

Analysis • Joinpoint regression to study trends in CAP-H incidence (overall and subgroups).

Results | CAP-H trends


- 469,944 CAP hospitalisations
- Male: 54.8% | ≥75 years: 65.3%. Frequent comorbidities: congestive heart failure (26.4%), diabetes (25.5%), and chronic pulmonary disease (19.2%)

Incidence rate of CAP-H decreased from 7.1 (2012) to 5.6 (2018)

Sex and age group

Decrease for both genders and all age groups

Comorbidities



CPD: Chronic pulmonary disease. CHF: Congestive heart failure. PVD: Peripheral vascular disease. DIAB: Complicated and uncomplicated diabetes. REUMA: Rheumatoid arthritis/collagen vascular diseases. AIDS: Human immunodeficiency virus/ Acquired immunodeficiency syndrome. TUMOR: Solid tumor without metastases and metastatic tumor. LD: Liver disease. CRD: chronic renal disease.

- Decrease for patients with diabetes and AIDS/HIV
- Increase for patients with chronic renal disease
- For the remaining 6 comorbidities, an upward trend was followed by a decreasing trend.

Methods | CVD after CAP-H

Study design • Self controlled case series

Population • Adults (≥18y) living in mainland Portugal.
• Hospitalised with CAP and hospitalised with stroke or myocardial infarction (MI) in a public hospital between 2010-18.

Exposure, periods, and outcome • Exposure: CAP hospitalization.
• Observation period: 2 years (of which 1 year after discharge).
• Exposure periods: 14, 28 and 91 days after discharge. Baseline periods: remaining days of observation period.
• Outcome: Acute cardiovascular (stroke or MI) hospitalisations.

Analysis • Incidence rate ratios and 95% confidence intervals (95%CI) were computed using a conditional Poisson regression

Results | CVD after CAP-H

- 13,494 patients
- Male: stroke – 52%, MI – 55%
- ≥75 years: stroke – 78%, MI – 70%

Stroke/MI hospitalisation incidence was higher following a CAP hospitalisation, compared to the baseline period

	14 days	28 days	91 days
Stroke:	2.55 (2.33-2.80)	2.06 (1.92-2.22)	1.37 (1.30-1.44)
MI:	3.23 (2.78-3.75)	2.62 (2.32-2.95)	1.75 (1.60-1.91)
Incidence rate ratio (95%CI)			

Take away messages

- Incidence of CAP hospitalizations declined in 2010-18 in most groups
- Higher risk of cardiovascular events following a CAP hospitalization, especially in the first two weeks after discharge
- Need to undertake continued and coordinated efforts to reduce the need for CAP hospitalisation and, when it cannot be avoided, to address possible cardiovascular risks